A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
← catalyst calendarNCT06257875 · readout ≤ 407 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
156actual
Sites
191
Countries
Australia, Austria, Belgium +27
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-23 | actual | When the study began enrolling |
| Primary completion | Sep 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ulcerative Colitis
Interventions
- Drug: Lutikizumab — also filed as ABT-981
- Drug: Lutikizumab — also filed as ABT-981
- Drug: Adalimumab — also filed as Humira
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants who Achieve Endoscopic Improvement
measured Week 12
Number of Participants with Adverse Events (AEs)
measured Up to approximately Week 104
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed